MedTrace Logo

Omega-3 Fatty Acids and Insulin Sensitivity

NCT01686568 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2017-03-03

Study results available
· View outcomes & findings →

Summary

This study is being done to understand the effects of dietary omega-3 fats on insulin sensitivity in adult men and women.

Conditions

Interventions

DRUG

Omega-3

Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.

DRUG

placebo

Sponsors & Collaborators

  • National Center for Advancing Translational Sciences (NCATS)

    collaborator NIH

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Building Interdisciplinary Research Careers in Women's Health

    collaborator UNKNOWN

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Ian Lanza, PhD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-12-21
Primary Completion
2014-10-30
Completion
2015-06-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01686568 on ClinicalTrials.gov